entertainment -WSS

entertainment

author：hotspot 2025-09-27 22:57:05 - browse：67

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Hospitals, health systems can help patients avoid medical debt

hotspot

focus

WSS

What affirmative action's end means to a medical student

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Dexcom's push to bring CGM to type 2 diabetes patients

Alexander Hamilton and the argument for universal insurance

The mammogram wars are not over

Dexcom's push to bring CGM to type 2 diabetes patients

Wikipedia

entertainment

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Security flaws in third

Medicare details structure of new drug price negotiation program

Dexcom's push to bring CGM to type 2 diabetes patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The wait for US passports is creating travel purgatory and snarling summer plans

Medical records are filled with copy

Vertex cell therapy lets patients with type 1 diabetes stop insulin

How one medical school became remarkably diverse

Hospitals, health systems can help patients avoid medical debt

knowledge

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Canadians with cystic fibrosis outlive Americans by a decade

Vertex cell therapy lets patients with type 1 diabetes stop insulin

'Screen and refer' systems are hurting patients

CDC: Cases of alpha

Drug cartel violence flares in western Mexico after vigilante leader's killing

hotspot

focus

focus

focus